Navigation Links
Early-stage immune system control of HIV may depend on inherited factors

How well an individual's immune system controls HIV during the earliest phases of infection appears to depend on both the specific versions of key immune-system molecules called HLA Class I that have been inherited, as well as on the fragments of viral protein those molecules display to the T lymphocytes that usually destroy infected cells. In a report in the November issue of PLOS Medicine, researchers from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) report that specific HLA Class I/HIV viral fragment combinations are associated with a more powerful antiviral response, findings that may help develop vaccines against HIV.

"We found that only a limited number of viral protein fragments from HIV-1 are targeted by the immune system in early infection and that the versions of HLA Class I previously associated with slower HIV-1 disease progression also contribute more to this initial antiviral immune response," says Marcus Altfeld, MD, PhD, of PARC/MGH, the paper's lead author.

An essential aspect of the immune response involves educating T cells to recognize pathogens or other "non-self" proteins. This is done by means of human leukocyte antigen (HLA) receptors that sit on the surface of virtually every cell. Immune system cells that ingest bacteria or parasites digest those pathogens and display protein fragments on their surface membranes via HLA Class II proteins. Virally infected cells display viral proteins on HLA Class I molecules, which activate the CD8 cytotoxic T lymphocytes that usually destroy infected cells. Although the CD8 response against HIV is ultimately ineffective in protecting infection, several studies have suggested that it plays a key role in determining how quickly the disease progresses after initial infection.

HLA ?also called major histocompatibility complex (MHC) ?proteins are also the primary markers of tissues as "self." Unique to each individual, these are the factors tha
'"/>

Source:Massachusetts General Hospital


Page: 1 2 3

Related biology news :

1. Early-stage sperm cells created from human bone marrow
2. Fox Chase Cancer Center scientists identify immune-system mutation
3. Genetically modified natural killer immune cells attack, kill leukemia cells
4. Studies reveal methods viruses use to sidestep immune system
5. Jumping gene helps explain immune systems abilities
6. Scientists solve structure of key protein in innate immune response
7. Rats infected as newborns grew up vulnerable to memory problems during an immune challenge
8. NYU study reveals how brains immune system fights viral encephalitis
9. Chemists identify immune system mechanism for methamphetamine binges
10. Multi-purpose protein regulates new protein synthesis and immune cell development
11. Genetic defects give the immune system the green light to attack the pancreas

Post Your Comments:
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...eath Research Laboratory in the University of Haif...estigious Johnson & Johnson Focused Funding grant ... damage in Parkinson,s disease. The award, which i...novation and excellence in science, was announced ...th at an event at the Hyatt Regency Hotel in New J...
(Date:11/25/2009)...fessors recently received funding from the Nationa...neficial to understanding the environment. The thr...d, assistant professor in the Department of Biolog...eparate research projects. , His first project, ...nd Functions from the Leaf to the Landscape," will...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Rigel to Present at Jefferies Healthcare Conference 48415 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 1Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 2
... subjects to operate a robot-controlled joystick, ...er the brain "learns" to control certain muscle mo...son over the long haul. The results, the investiga...r people who have lost motor abilities to brain in... the May 23 issue of PLoS Biology, the researchers...
...archers have found a group of cells in the intesti...lls, cells that help fight infection. , The resear...journal Immunity, released today. , "This connect... will help in studying and developing treatments f...m," said Stephen McSorley, Ph.D., professor of med...
...t four factors, researchers have successfully indu...or adult mice to behave like embryonic stem cells....ediate early publication of the journal Cell, publ...rchers designate "induced pluripotent stem cells" ...haracteristics typical of embryonic stem cells, th...
Other Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3With few factors, adult cells take on character of embryonic stem cells 2
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
(Date:11/24/2009)... Chemical Abstracts Service ...reports that China,s patent office is now the worl...ons in chemistry. China trailed Japan,s patent off...(WIPO), and the United States Patent and Trademark... the USPTO in 2005, WIPO in 2006, and exceeded Jap...
(Date:11/23/2009)...HAMPAIGN, Ill. You can think of it as origami ve...sity of Illinois have developed a technique for fa...licon structures from thin films by coupling photo...apillary interactions. , The films, only a few mi...not possible with thicker pieces of the same mater...
(Date:11/23/2009)..., INCLINEVILLAGE,Nev.,Nov.23/PRNewswire-FirstCa...ouncedthatNASDAQhasestablishedNovember27,2009asthe...tockholdersresultingfromthesecuritizationtransacti...nDecember15,2009toallstockholdersofrecordonthereco...rshareamountofthedividendat$1.67pershareofcommonst...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...., Jan. 13 Nektar Therapeutics,(Nasdaq: NKTR ) ... 2 clinical,trial of NKTR-102 in platinum-resistan...been obtained and dosing will begin shortly in two...evaluate NKTR-102 versus irinotecan in,second-line...ation, and a,Phase 2 study in metastatic breast ca...
.... 13 Burnham Institute for Medical Research (Burn...greement with Johnson & Johnson Pharmaceutical...he agreement is Burnham,s first broad-based partne...der this multi-year agreement, Burnham will provid...screening technologies to investigate certain drug...
...., Jan. 13 Neurobiological,Technologies, Inc. (Na...owing a,detailed analysis of the recent interim re...any has decided not to develop Viprinex further fo... was recently studied in a,clinical trial to deter...,outcome when given within six hours of a stroke, ...
Other Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2Neurobiological Technologies Announces Suspension of Viprinex Development 2Neurobiological Technologies Announces Suspension of Viprinex Development 3
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
27-mer duplex from B-Bridge International
Propidium Iodide Buffer from BioLegend
Luminex 100 Instrument System from Upstate
Biology Products: